ArticleBioinformatics (Oxford, England)2014
Personalized identification of altered pathways in cancer using accumulated normal tissue data.
Article in Bioinformatics (Oxford, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Personalized identification of differentially expressed pathways in pediatric sepsis.Molecular medicine reports · 2017Pooled it
- ssNetShift: single-sample metabolic network rewiring reveals hidden prognostic subtypes beyond clinical staging in gastric cancer.Briefings in bioinformatics · 2026Article
- NetActivity enhances transcriptional signals by combining gene expression into robust gene set activity scores through interpretable autoencoders.Nucleic acids research · 2024Article
- Individualized pathway activity algorithm identifies oncogenic pathways in pan-cancer analysis.EBioMedicine · 2022Article
- Individualized multi-omic pathway deviation scores using multiple factor analysis.Biostatistics (Oxford, England) · 2022Article
- Genomic Analysis of Abnormal DNAM Methylation in Parathyroid Tumors.International journal of endocrinology · 2022Article
- Highly accurate diagnosis of papillary thyroid carcinomas based on personalized pathways coupled with machine learning.Briefings in bioinformatics · 2021Article
- Article
- GMIEC: a shiny application for the identification of gene-targeted drugs for precision medicine.BMC genomics · 2020Article
- Predicting Stage-Specific Recurrent Aberrations From Somatic Copy Number Dataset.Frontiers in genetics · 2020Article
- Identifying Cancer Driver lncRNAs Bridged by Functional Effectors through Integrating Multi-omics Data in Human Cancers.Molecular therapy. Nucleic acids · 2019Article
- Developing a 'personalome' for precision medicine: emerging methods that compute interpretable effect sizes from single-subject transcriptomes.Briefings in bioinformatics · 2019Review
- Integrating gene regulatory pathways into differential network analysis of gene expression data.Scientific reports · 2019Article
- Crosstalk analysis of dysregulated pathways in preeclampsia.Experimental and therapeutic medicine · 2019Article
- Prediction of response to anti-cancer drugs becomes robust via network integration of molecular data.Scientific reports · 2019Article
- Identification of potential biomarkers of lung adenocarcinoma brain metastases via microarray analysis of cDNA expression profiles.Oncology letters · 2019Article
- Comprehensive Molecular Profiling for Relapsed/Refractory Pediatric Burkitt Lymphomas-Retrospective Analysis of Three Real-Life Clinical Cases-Addressing Issues on Randomization and Customization at the Bedside.Frontiers in oncology · 2019Article
- Individualized Drug Repositioning For Rheumatoid Arthritis Using Weighted Kolmogorov-Smirnov Algorithm.Pharmacogenomics and personalized medicine · 2019Article
- A Single-Subject Method to Detect Pathways Enriched With Alternatively Spliced Genes.Frontiers in genetics · 2019Article
- Systemic tracking of diagnostic function modules for post-menopausal osteoporosis in a differential co-expression network view.Experimental and therapeutic medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
motivationIdentifying altered pathways in an individual is important for understanding disease mechanisms and for the future application of custom therapeutic decisions. Existing pathway analysis techniques are mainly focused on discovering altered pathways between normal and cancer groups and are not suitable for identifying the pathway aberrance that may occur in an individual sample. A simple way to identify individual's pathway aberrance is to compare normal and tumor data from the same individual. However, the matched normal data from the same individual are often unavailable in clinical situation. Therefore, we suggest a new approach for the personalized identification of altered pathways, making special use of accumulated normal data in cases when a patient's matched normal data are unavailable. The philosophy behind our method is to quantify the aberrance of an individual sample's pathway by comparing it with accumulated normal samples. We propose and examine personalized extensions of pathway statistics, overrepresentation analysis and functional class scoring, to generate individualized pathway aberrance score.
resultsCollected microarray data of normal tissue of lung and colon mucosa are served as reference to investigate a number of cancer individuals of lung adenocarcinoma (LUAD) and colon cancer, respectively. Our method concurrently captures known facts of cancer survival pathways and identifies the pathway aberrances that represent cancer differentiation status and survival. It also provides more improved validation rate of survival-related pathways than when a single cancer sample is interpreted in the context of cancer-only cohort. In addition, our method is useful in classifying unknown samples into cancer or normal groups. Particularly, we identified 'amino acid synthesis and interconversion' pathway is a good indicator of LUAD (Area Under the Curve (AUC) 0.982 at independent validation). Clinical importance of the method is providing pathway interpretation of single cancer, even though its matched normal data are unavailable. AVAILABILITY AND IMPLEMENTATION: The method was implemented using the R software, available at our Web site: http://bibs.snu.ac.kr/ipas. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.